Ista Istalol “approvable”
Ista's Istalol (timolol) will respond to FDA "approvable" letter before end of the year, the company says. Approvable letter received in late July for the glaucoma treatment cites manufacturing and control issues. No additional clinical studies were requested...
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.